Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6262 ARTÍCULOS , VIENDO DEL 2356 AL 2370

Therapeutic potential of Bergenin in the management of neurological-based diseases and disorders

Rezaiezadeh H, Langarizadeh MA, Tavakoli MR, Sabokro M, Banazadeh M, Kohlmeier KA, Shabani M.

Naunyn Schmiedebergs Arch Pharmacol. 2024 Nov;397(11):8349-8366. doi: 10.1007/s00210-024-03197-2. Epub 2024 Jun 8.

Targeting Mitochondrial Dysfunction and Reactive Oxygen Species for Neurodegenerative Disease Treatment

Choi EH, Kim MH, Park SJ.

Int J Mol Sci. 2024 Jul 21;25(14):7952. doi: 10.3390/ijms25147952.

Emerging roles of the G-protein-coupled receptor 37 in neurological diseases and pain

Wang X, Ju J, Xie Y, Hang L.

Neuroscience. 2024 Nov 1;559:199-208. doi: 10.1016/j.neuroscience.2024.08.032. Epub 2024 Sep 6.

Type 2 diabetes mellitus and neurodegenerative disorders: The mitochondrial connection

Baduini IR, Castro Vildosola JE, Kavehmoghaddam S, Kiliç F, Nadeem SA, Nizama JJ, Rowand MA, Annapureddy D, Bryan CA, Do LH, Hsiao S, Jonnalagadda SA, Kasturi A, Mandava N, Muppavaram S, Ramirez B, Siner A, Suoto CN, Tamajal N, Scoma ER, Da Costa RT, Solesio ME.

Pharmacol Res. 2024 Nov;209:107439. doi: 10.1016/j.phrs.2024.107439. Epub 2024 Sep 30.

The Impact of the Blood-Brain Barrier and Its Dysfunction in Parkinson's Disease: Contributions to Pathogenesis and Progression

Khalid Iqbal M, Khan B, Hifsa, YuXuan G, Mujahid M, Kiyani MM, Khan H, Bashir S.

ACS Omega. 2024 Nov 5;9(46):45663-45672. doi: 10.1021/acsomega.4c06546. eCollection 2024 Nov 19.

Does Bisphenol A (BPA) Exposure Cause Human Diseases?

Stein TP.

Biomedicines. 2024 Nov 25;12(12):2678. doi: 10.3390/biomedicines12122678.

The mechanisms of white matter injury and immune system crosstalk in promoting the progression of Parkinson's disease: a narrative review

Ma W, Geng Y, Liu Y, Pan H, Wang Q, Zhang Y, Wang L.

Front Aging Neurosci. 2024 May 28;16:1345918. doi: 10.3389/fnagi.2024.1345918. eCollection 2024.

Pharmacological mechanisms of puerarin in the treatment of Parkinson's disease: An overview

Zhang N, Guo P, Zhao Y, Qiu X, Shao S, Liu Z, Gao Z.

Biomed Pharmacother. 2024 Aug;177:117101. doi: 10.1016/j.biopha.2024.117101. Epub 2024 Jul 14.

Evaluation of retinal microvascular changes with OCT-A in Parkinson disease and essential tremor

Erdem M, Soker EB, Ozdogru D, Balal M, Ciloglu E.

Medicine (Baltimore). 2024 Dec 6;103(49):e40752. doi: 10.1097/MD.0000000000040752.

Comparison of Efficacy and Safety of Device-Based Interventions Versus Pharmacological Therapy in the Management of Patients With Advanced Parkinson's Disease: A Literature Review

Farooqi W, Alabdullkarim FA, Abukaram TM, Gubran L, Alsulami DS, Albehairi SA, Alabdulkarim FA, Wadaan AM.

Cureus. 2024 Dec 19;16(12):e76044. doi: 10.7759/cureus.76044. eCollection 2024 Dec.

[Recent advance in neurological complications following wasp stings]

Zhang SM, Fang ZC, Yang XY.

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2024 May 20;42(5):395-400. doi: 10.3760/cma.j.cn121094-20230626-00218.

Asymmetry in Atypical Parkinsonian Syndromes-A Review

Chunowski P, Madetko-Alster N, Alster P.

J Clin Med. 2024 Sep 28;13(19):5798. doi: 10.3390/jcm13195798.

The QT interval in Parkinson's disease: a systematic review

Rabkin SW.

J Geriatr Cardiol. 2024 Sep 28;21(9):855-864. doi: 10.26599/1671-5411.2024.09.003.

If Art Were a Drug: Implications for Parkinson's Disease

Gros P, Spee BTM, Bloem BR, Kalia LV.

J Parkinsons Dis. 2024;14(s1):S159-S172. doi: 10.3233/JPD-240031.

Evidence linking gut-brain axis and Crohn's disease, focusing on neurotrophic dysfunctions and radiological imaging analysis - a systematic review

Silva JF, de Souza WM, Mello JDC, Ceccato HD, Oliveira PSP, Ayrizono MLS, Leal RF.

Am J Transl Res. 2024 Oct 15;16(10):6029-6040. doi: 10.62347/OWYY4960. eCollection 2024.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias